Objetivo
A new procedure was implemented to clone some of the genes included in microdeletions if the chromosome X present in patients with contigous gene deletion syndromes.
This procedure relied on the use of a modification of the PERT technique, the PERT reassociated sequences being selected through several cycles of nonspecific polymerase chain reaction (PCR). To optimize the conditions for sequence enrichment, several modifications of the PERT protocol were designed.
The following areas have been mastered:
the conditions for reassociation of chromosome X-enriched deoxyribonucleic acid (DNA) by PERT;
the specific amplification of the products obtained in these experiments (this required to test the efficacy of various adapter molecules and the conditions of PCR);
the experimental conditions for Alu-PCR amplification of somatic cell hybrids having retained the human X chromosomes.
The main results are presented by the identification of candidate genes for the recessive forms of dystrophic epidermolysis bullosa and epidermolysis bullosa simplex by the localization on the X chromosome of a new form of hypophosphatemic rickets and by the identification of the gene for autosomal dominant Hirschsprung disease (HSCR) on chromosome 10.
The RET protooncogene was recognized as being responsible for HSCR. While the mutations of RET protooncogene observed in HSCR patients ar spread through the different domains of the gene, 3 other inherited disorders namely multiple endocrine neoplasia type 2A (MEN 2A), type 2B (MEN 2B) and familiar medullary thyroid carcinoma (FMTC) are characterized by mutations in specific domains of RET. As an example a single mutation in exon 16 of RET is present in 95% of the patients with MEN 2B.
The tasks of the project are essentially the following:
To identify new polymorphic DNA markers on the X chromosome. A newly discovered humanspecific and ubiquitous polymorphic core sequence is being used in one of the two participant laboratories to screen a humanhamster cosmid library retaining the X as its sole human cmponent. This should lead to the identification and cloning of a number of hypermorphic marker loci throughout the chromosome. Such markers will be physically mapped and subsequently used for genetic studies in CEPH pedigrees and in families segregating for X-inked disease genes.
In addition screenings for such new hypermorphic markers will be performed in particular regions of interest from which YAC clones have already been isolated such as the Xq13 region (where the gene for Menkes disease has been mapped), the Xq25 region (where the gene for Duncan syndrome has been mapped) and the Xq28 region (where several disease genes, among them the Emery Dreifuss muscular dystrophy gene, have been localized). Cell lines from patients and other members of pedigrees with recurrence of such disorders are already available for linkage studies.
To implement new techniques allowing the cloning of the genes included in microdeletions of the X chromosome present in patients with a contiguous gene syndrome. Two approaches will be developed. The first is based on a modification of the PERT (Phenol Enhanced Reassociation Technique) which will be improved in different ways: the starting material will be enriched in Xspecific sequences by chromosome sorting and the PERTreassociated sequences will be selected through several cycles of nonspecific PCR. With the second approach, a modified reassociation technique will be developed starting from genomic DNA from patients bearing a microdeletion in the X chromosome and cDNA derived from a tissue in which the disease gene of interest is normally expressed.
These approaches are already being developed in both laboratories through preliminary experiments aimed at perfecting the techniques. To this end, a large deletion from patients with Duchenne muscular dystrophy, glycerolkinase deficiency and adrenal hypoplasia will be used. Additional microdeletions are available in the two laboratories from patients with Menkes disease, Duncan syndrome, Norrie disease and Xlinked agammaglobulinemia combined with isolated growth hormone deficiency.
To construct an X chromosomespecific library in the bacteriophage P1, which allows the cloning of DNA fragments as large as 100 Kbp. This will make it possible to develop physical maps corresponding to regions of interest, making use of the DNA markers generated as described under 1.
Ámbito científico (EuroSciVoc)
CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural. Véas: El vocabulario científico europeo..
CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural. Véas: El vocabulario científico europeo..
- ciencias naturales ciencias biológicas genética ADN
- ciencias médicas y de la salud medicina básica neurología distrofia muscular distrofia muscular de duchenne
- ciencias naturales ciencias biológicas genética mutación
- ciencias naturales ciencias biológicas genética cromosoma
- ciencias naturales ciencias biológicas genética genoma
Para utilizar esta función, debe iniciar sesión o registrarse
Programa(s)
Programas de financiación plurianuales que definen las prioridades de la UE en materia de investigación e innovación.
Programas de financiación plurianuales que definen las prioridades de la UE en materia de investigación e innovación.
Tema(s)
Las convocatorias de propuestas se dividen en temas. Un tema define una materia o área específica para la que los solicitantes pueden presentar propuestas. La descripción de un tema comprende su alcance específico y la repercusión prevista del proyecto financiado.
Datos no disponibles
Las convocatorias de propuestas se dividen en temas. Un tema define una materia o área específica para la que los solicitantes pueden presentar propuestas. La descripción de un tema comprende su alcance específico y la repercusión prevista del proyecto financiado.
Convocatoria de propuestas
Procedimiento para invitar a los solicitantes a presentar propuestas de proyectos con el objetivo de obtener financiación de la UE.
Datos no disponibles
Procedimiento para invitar a los solicitantes a presentar propuestas de proyectos con el objetivo de obtener financiación de la UE.
Régimen de financiación
Régimen de financiación (o «Tipo de acción») dentro de un programa con características comunes. Especifica: el alcance de lo que se financia; el porcentaje de reembolso; los criterios específicos de evaluación para optar a la financiación; y el uso de formas simplificadas de costes como los importes a tanto alzado.
Régimen de financiación (o «Tipo de acción») dentro de un programa con características comunes. Especifica: el alcance de lo que se financia; el porcentaje de reembolso; los criterios específicos de evaluación para optar a la financiación; y el uso de formas simplificadas de costes como los importes a tanto alzado.
Coordinador
16148 Genova Quarto
Italia
Los costes totales en que ha incurrido esta organización para participar en el proyecto, incluidos los costes directos e indirectos. Este importe es un subconjunto del presupuesto total del proyecto.